Jubilant Pharma

Rating agency foresees firm's financial leverage worsening as a rise in capex will coincide with lower profitability

While the term loan and bonds aggregate to USD 350 million, about Rs 2,787 crore, the company is raising another tranche of USD 50 million (about Rs 400 crore) for capital expenditure.

Drug firm Jubilant Pharmova on Friday reported a consolidated net profit of Rs 160.49 crore from continuing operations for the quarter ended June 30, 2021. The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing. Revenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a year ago, it added. Figures for the quarter are not comparable with previous periods since the Life Science Ingredients business was demerged with effect from February 1, 2021 pursuant to the composite scheme of arrangement during the previous year, the filing said. "During this quarter, in addition to YoY increase, we also reported sequential improvement in the specialty pharma segment with gradual recovery across radiopharmaceuticals, radiopharmacy and allergy business," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman & MD Hari S Bhartia said in a ...

Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the USFDA

Company's product is a generic version of Daiichi Sankyo's Azor

Shares of Jubilant Life Sciences were trading 1.89 per cent higher at Rs 601 on BSE